Literature DB >> 9362396

Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation.

Y Rozenman1, D Sapoznikov, M Mosseri, D Gilon, C Lotan, H Nassar, A T Weiss, Y Hasin, M S Gotsman.   

Abstract

OBJECTIVES: We sought to compare the angiographic outcome of diabetic patients (treated with insulin or oral hypoglycemic agents) after successful coronary angioplasty with that in nondiabetic patients. The analysis included the outcome of the dilated (restenosis) and nondilated narrowings (disease progression).
BACKGROUND: Recent data have confirmed that diabetes mellitus is an important risk factor for long-term adverse events. These adverse events are more common after balloon angioplasty than after bypass surgery (Bypass Angioplasty Revascularization Investigation [BARI]).
METHODS: We examined retrospectively 353 coronary angiograms of 248 patients (55 diabetic, 193 nondiabetic) who were referred for diagnostic angiography >1 month after successful angioplasty (1.4 +/- 0.6 [mean +/- SD] repeat angiograms/patient). Restenosis and disease progression/regression were compared between groups by means of quantitative angiography.
RESULTS: Baseline clinical and angiographic characteristics were similar in both groups. There was a nonsignificant trend for a higher restenosis rate of dilated narrowings in diabetic patients. There were no significant changes between diabetic and nondiabetic patients in the rates of progression and regression of narrowings that were not dilated during the initial angioplasty. The main difference was in the rate of appearance of new narrowings: There was a 22% increase in the number of narrowings on the follow-up angiogram in diabetic patients (38 new, 174 preexisting narrowings) compared with 12% (86 new, 734 preexisting narrowings) in nondiabetic patients (p < 0.004). Diabetes mellitus and the performance of angioplasty in the artery had an additive risk for development of new narrowings, which were identified in 15 (16.9%) of 89 arteries with and 16 (13.2%) of 121 without angioplasty in diabetic patients and in 42 (12.7%) of 331 arteries with and 38 (7.3%) of 518 without angioplasty in nondiabetic patients (p = 0.009).
CONCLUSIONS: The combination of diabetes mellitus and an artery that was instrumented during balloon angioplasty is additive and increases the risk of formation of new narrowing in that artery. This finding may explain the high adverse event rates observed in diabetic patients in the angioplasty arm of the BARI study, most of whom had angioplasty performed in at least two arteries.

Entities:  

Mesh:

Year:  1997        PMID: 9362396     DOI: 10.1016/s0735-1097(97)00342-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Trends in postacute myocardial infarction management and mortality in patients with diabetes. A population-based study from 1995 to 2001.

Authors:  Najwa Ouhoummane; Belkacem Abdous; Rabia Louchini; Louis Rochette; Paul Poirier
Journal:  Can J Cardiol       Date:  2010-12       Impact factor: 5.223

2.  Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus.

Authors:  Y Rozenman; D Sapoznikov; M S Gotsman
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

Review 3.  Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.

Authors:  Thoralf Wendt; Loredana Bucciarelli; Wu Qu; Yan Lu; Shi Fang Yan; David M Stern; Ann Marie Schmidt
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

Review 4.  Advanced glycation end products and C-peptide-modulators in diabetic vasculopathy and atherogenesis.

Authors:  Daniel Walcher; Nikolaus Marx
Journal:  Semin Immunopathol       Date:  2009-04-05       Impact factor: 9.623

Review 5.  RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.

Authors:  Hidenori Koyama; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Mol Med       Date:  2007 Nov-Dec       Impact factor: 6.354

Review 6.  Advances and continued controversy in coronary revascularization of patients with diabetes mellitus.

Authors:  John L Petersen; Darren K McGuire; Robert A Harrington
Journal:  Curr Diab Rep       Date:  2003-10       Impact factor: 5.430

7.  MRI plaque imaging reveals high-risk carotid plaques especially in diabetic patients irrespective of the degree of stenosis.

Authors:  L Esposito; T Saam; P Heider; Angelina Bockelbrink; Jaroslav Pelisek; D Sepp; R Feurer; C Winkler; T Liebig; K Holzer; O Pauly; S Sadikovic; B Hemmer; H Poppert
Journal:  BMC Med Imaging       Date:  2010-11-30       Impact factor: 1.930

8.  Association of inflammatory markers and poor outcome in diabetic patients presenting with ST segment elevation myocardial infarction.

Authors:  Yulia Belenkova; Viktoria Karetnikova; Aleksey Diachenko; Olga Gruzdeva; Olga Blagoveshchenskaya; Tatiana Molodtsova; Evgenya Uchasova; Olga Barbarash
Journal:  J Inflamm Res       Date:  2015-05-20

9.  Factors Associated With Coronary Artery Disease Progression Assessed By Serial Coronary Computed Tomography Angiography.

Authors:  Gabriel Cordeiro Camargo; Tamara Rothstein; Maria Eduarda Derenne; Leticia Sabioni; João A C Lima; Ronaldo de Souza Leão Lima; Ilan Gottlieb
Journal:  Arq Bras Cardiol       Date:  2017-05-04       Impact factor: 2.000

10.  Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.

Authors:  Doo Sun Sim; Myung Ho Jeong; Weon Kim; Jay Young Rhew; Ju Hyup Yum; Ju Han Kim; Jeong Gwan Cho; Young Keun Ahn; Jong Chun Park; Byoung Hee Ahn; Sang Hyung Kim; Jung Chaee Kang
Journal:  Korean J Intern Med       Date:  2003-09       Impact factor: 2.884

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.